Co-Founder, President & CEO
Donald McCaffrey is co-founder, president and chief executive of Resverlogix Corp. He has more than 30 years of experience in drug discovery and development, and international conference and tradeshow management across multiple industries, including biotechnology.
Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over $185 million. In addition to garnering appropriate financing for Resverlogix's aggressive development plan, Don has strategically directed the company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms.
Don's expertise in corporate operations has attracted an international team of R&D experts to Resverlogix. This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease. Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.
Don's career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal College, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.